Abstract
Background
Nearly 50% of women with breast cancer show depressive symptoms after diagnosis and treatment. The purpose of this study was to clarify how psychosocial factors (body image, sexuality, and social relationships) and genetic factors (functional polymorphism of the serotonin transporter-linked promoter region) influence depression.
Methods
The participants were categorized by DSM-IV diagnoses; scored according to their depressive symptoms, body image and social and sexual function (BIRS), self-esteem, and quality of life; and genotyped by functional polymorphism of the serotonin transporter promoter.
Results
Patients with depressive symptoms showed low self-esteem, poor body image, relationship problems, and low quality of life. Genotype frequencies did not differ between two groups categorized by the presence or absence of depressive symptoms. However, the patients with the short allele of the 5-HTTLPR had significantly higher HAM-D scores (F = 7.59, p = 0.047).
Conclusion
The results suggest that psychosocial factors related to breast cancer treatment such as body image, self-esteem, and interpersonal relationship influence the development of depressive symptoms. The 5-HTTLPR may be associated with the severity of depressive symptoms rather than susceptibility to the development of depressive symptoms.
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108
Shin HR, Jung KW, Won YJ, Park JG (2004) 139 KCCR-affiliated Hospitals. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 36:103–114
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55(1):10–30
Ganz PA (2003) Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory. Eur J Cancer 39(15):2136–2141
Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32:57–71
Schou I, Ekeberg O, Ruland CM, Sandvik L, Karesen R (2004) Pessimism as a predictor of emotional morbidity one year following breast cancer surgery. Psychooncology 13(5):309–320
Ayres A, Hoon PW, Franzoni JB, Matheny KB, Cotanch PH, Takayanagi S (1994) Influence of mood and adjustment to cancer on compliance with chemotherapy among breast cancer patients. J Psychosom Res 38(5):393–402
Ell K, Sanchez K, Vourlekis B, Lee PJ, Dwight-Johnson M, Lagomasino I et al (2005) Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol 23(13):3052–3060
Hjerl K, Andersen EW, Keiding N, Mouridsen HT, Mortensen PB, Jorgensen T (2003) Depression as a prognostic factor for breast cancer mortality. Psychosomatics 44(1):24–30
Bardwell WA, Natarajan L, Dimsdale JE, Rock CL, Mortimer JE, Hollenbach K et al (2006) Objective cancer-related variables are not associated with depressive symptoms in women treated for early-stage breast cancer. J Clin Oncol 24(16):2420–2427
Vahdaninia M, Omidvari S, Montazeri A (2010) What do predict anxiety and depression in breast cancer patients? A follow-up study. Soc Psychiatry Psychiat Epidemiol 45(3):355–361
Montazeri A (2008) Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 27:32
Malhi GS, Moore J, McGuffin P (2000) The genetics of major depressive disorder. Curr Psychiatry Rep 2(2):165–169
Morris PL, Robinson RG, Raphael B, Samuels J, Molloy P (1992) The relationship between risk factors for affective disorder and poststroke depression in hospitalised stroke patients. Aust N Z J Psychiatry 26(2):208–217
Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter. Clin Chem 40(2):288–295
Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G et al (1995) Beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 100(3):247–256
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292):1527–1531
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631):386–389
Anguelova M, Benkelfat C, Turecki G (2003) A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: Ii. Suicidal behavior. Mol Psychiatry 8(7):646–653
Serretti A, Calati R, Mandelli L, De Ronchi D (2006) Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 7(12):1659–1669
Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL (1999) Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 88(1):83–87
Grassi L, Rossi E, Cobianchi M, Aguiari L, Capozzo M, Martinis E et al (2010) Depression and serotonin transporter (5-HTTLPR) polymorphism in breast cancer patients. J Affect Disord 124(3):346–350
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370
Lloyd-Williams M, Friedman T, Rudd N (2001) An analysis of the validity of the Hospital Anxiety and Depression Scale as a screening tool in patients with advanced metastatic cancer. J Pain Symptom Manage 22(6):990–996
Aaronson NK, Ahmedzai S, Bergman B, Li Q, Bengel D, Murphy DL (1983) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M et al (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14(10):2756–2768
Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY et al (2004) Validation of the Korean version of the EORTC-QLQ-C30. Qual Life Res 13(4):863–868
Yun YH, Bae SH, Kang IO, Shin KH, Lee R, Kwon SI et al (2004) Cross-cultural application of the korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast-Cancer-Specific Quality of Life Qquestionnaire (EORTC QLQ-C30). Support Care Cancer 12(6):441–445
Collier DA, Stöber G, Li T, Heils A, Catalano M, Di Bella D et al (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1(6):453–460
Acknowledgements
This study was supported by a faculty research grant of from the Yonsei University College of Medicine (No. 6-2008-0139).
Financial disclosure/Conflict of interest
We have no financial disclosures and conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, K.R., Chung, H.C., Lee, E. et al. Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism. Support Care Cancer 20, 2177–2182 (2012). https://doi.org/10.1007/s00520-011-1329-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-011-1329-z